Thirty four drugs of Beijing Centergate Technologies Holding's (SHE:000931) pharmaceutical subsidiaries were included in China's National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog for 2024, according to a Shenzhen Stock Exchange filing on Wednesday.
The list included bisoprolol fumarate tablets, benidipine hydrochloride tablets, oxycodone hydrochloride tablets, and naloxone hydrochloride injection, among others.
Some of the drugs were already included in the 2023 catalog.
The catalog for the year will be implemented on Jan. 1, 2025, the filing said.
The residential and office building developer's shares jumped over 4% in recent trade.
Comments